BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.890
-0.050 (-1.27%)
Aug 14, 2025, 2:10 PM - Market open
BioLineRx Revenue
BioLineRx had revenue of $304.00K in the quarter ending June 30, 2025, a decrease of -94.36%. This brings the company's revenue in the last twelve months to $17.25M, up 1.19% year-over-year. In the year 2024, BioLineRx had annual revenue of $28.94M with 502.92% growth.
Revenue (ttm)
$17.25M
Revenue Growth
+1.19%
P/S Ratio
0.92
Revenue / Employee
$616,107
Employees
28
Market Cap
15.87M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
Dec 31, 2023 | 4.80M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
BLRX News
- 3 hours ago - BioLineRx Ltd. (BLRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 hours ago - BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 days ago - BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 - PRNewsWire
- 2 months ago - Why Is Nano-Cap BioLineRx Stock Surging On Friday? - Benzinga
- 2 months ago - BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer (PDAC) to be Presented at ASCO 2025 Annual Meeting - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - BioLineRx to Report First Quarter 2025 Results on May 27, 2025 - PRNewsWire